Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles

Fig. 2

Characterization of PLGA NPs: Fluorescein Diacetate (FDA) PLGA NPs were used as a model system to investigate the size and release profile of the NP platform described (a, b). In vitro cargo release of the NPs was evaluated in PBS at pH 7.4. FDA was steadily released over the course of 120 h. The percent of FDA released at 24, 48, 72, and 96 h was 24%, 37%, 50%, 59%, and 70% respectively (b)

Back to article page